There are currently 695 clinical trials in Orlando, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including AdventHealth Orlando, GSK Investigational Site, Orlando Clinical Research Center and Nemours Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
NCT03672773
Recruiting
This phase II trial studies how effective talazoparib and temozolomide are for treating participants with extensive-stage small cell lung cancer that has come back after an initial chemotherapy treatment. Talazoparib, a PARP inhibitor, may stop the growth of tumor cells by preventing them from repairing their DNA. Chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spre... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: Orlando Health, Inc. d/b/a Orlando Health UF Health Center, Orlando, Florida
Conditions: Recurrent Extensive Stage Small Cell Lung Carcinoma, Refractory Extensive Stage Small Cell Lung Carcinoma
Register for Updates
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
NCT05306574
Recruiting
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
Gender:
All
Ages:
Between 12 years and 70 years
Trial Updated:
11/16/2023
Locations: Orlando Site, Orlando, Florida
Conditions: Systemic Lupus Erythematosus
Register for Updates
7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels
NCT05480761
Recruiting
This is a Phase 4, U.S. only, multi-center study using a 7-day therapeutic response dose (TRD) of commercial Sucraid® to assess the response of treatment in 1100 symptomatic pediatric (6 months to 17 years old) subjects with low, moderate, and normal sucrase activity determined by a disaccharidase assay via EGD within 1 year of the Screening Visit. This study will also explore the relationship between known genetic CSID mutations and sucrase activities via (EGD) disaccharidase assay (low, modera... Read More
Gender:
All
Ages:
Between 6 months and 17 years
Trial Updated:
11/14/2023
Locations: Orlando Health, Orlando, Florida
Conditions: Congenital Sucrase-Isomaltase Deficiency, CSID, Sucrase Isomaltase Deficiency
Register for Updates
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
NCT05400330
Recruiting
The primary purpose of this long-term follow-up study is to assess the long-term safety profile of APOE4 homozygote participants who were administered gene therapy (LX1001) for the treatment of Alzheimer's disease in Study LX100101. A secondary objective is to assess the biomarker as shown by the conversion of CSF APOE isoforms from APOE4 to APOE2-APOE4. Additional secondary outcomes include amyloid PET scan, CSF markers (including Aβ42, Aβ42/Aβ40 ratio T--tau, and P-tau), and quantitative MRI (... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
11/13/2023
Locations: PPD- Orlando Research Unit, Orlando, Florida
Conditions: Alzheimer Disease
Register for Updates
HIV Prevention Intervention for Latino Male Couples
NCT06131931
Recruiting
The primary objective of this proposal is to test the efficacy of Connecting Latinxs en Pareja (CLP). CLP is a four-session intervention grounded in social cognitive theory and a relationship oriented ecological framework. The investigators will examine whether participants assigned to CLP report an increase in the proportion of HIV protected anal sex acts to those assigned to a Wellness Promotion (WP) time and attention matched control condition. The primary outcome, relates to use of HIV prot... Read More
Gender:
Male
Ages:
Between 18 years and 100 years
Trial Updated:
11/13/2023
Locations: University of Central Florida, Orlando, Florida
Conditions: HIV
Register for Updates
Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants
NCT05547165
Recruiting
Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory system of the baby, but is expected to close at full term birth. If the opening is tiny, the condition can be self-limiting. If not, medications/surgery are options for treatment. There are two ways... Read More
Gender:
All
Ages:
Between 7 days and 32 days
Trial Updated:
11/12/2023
Locations: Orlando Health, Orlando, Florida
Conditions: Ductus Arteriosus, Patent
Register for Updates
Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers
NCT05662865
Recruiting
The purpose of this study is to help us better understand how plasma ketones respond to a low-carb diet when combined with an SGLT2 inhibitor.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
11/07/2023
Locations: AdventHealth Translational Research Institute, Orlando, Florida
Conditions: Ketones, Metabolism
Register for Updates
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
NCT05159700
Recruiting
This is a Phase I, multicenter, open-label, 3+3 dose escalation study to determine the safety and preliminary efficacy of PRJ1-3024 in subjects with relapsed/refractory solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/07/2023
Locations: Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida
Conditions: Advanced Solid Tumor, Advanced Solid Malignancies
Register for Updates
A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
NCT05601219
Recruiting
This study consists of dose escalation evaluation to determine the safety and tolerability of ADA-011 as a monotherapy and in combination with a checkpoint inhibitor. Following dose escalation, one or more dose expansion cohorts in selected indications will be explored to further evaluate the safety, tolerability, and preliminary efficacy of ADA-011.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/07/2023
Locations: Florida Cancer Specialists, Orlando, Florida
Conditions: Solid Tumor, Adult
Register for Updates
A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease
NCT04537377
Recruiting
The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult patients with Wilson's Disease prior to and following background WD therapy withdrawal.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
11/06/2023
Locations: Advent Health, Orlando, Florida
Conditions: Wilson's Disease
Register for Updates
Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients
NCT06054529
Recruiting
To learn how altered metabolism in GBM causes tumor growth and resistance to drug therapy. In this pilot research study, we will dose GBM patients with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness
Gender:
All
Ages:
18 years and above
Trial Updated:
11/06/2023
Locations: AdventHealth Translational Research Institute, Orlando, Florida
Conditions: Glioblastoma Multiforme
Register for Updates
Extracellular Vesicles for HD
NCT06082713
Recruiting
The primary objective of this study is to discover blood-based biomarker of brain Huntingtin (HTT) protein using extracellular vesicles to be used in evaluating target engagement in HTT lowering clinical trials. Secondary objectives of this study include developing more accurate biomarkers of Huntington disease (HD) progression or conversion and to develop standard practices for extracellular vesicle biomarker discovery research. The investigators hypothesize that brain-derived extracellular v... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/04/2023
Locations: University of Central Florida, Orlando, Florida
Conditions: Huntington Disease
Register for Updates